PeptidePedia The community reference

Contributions of Chromatokid

User contributions·266 logged edits·page 3 of 3

Contributions by Chromatokid, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 41,208 edits includes activity predating the current log.

  1. 10:21, 18 Jan 2025 (diff | hist) Nantong Guangyuan Chemical 8,038 +986 correct the regional-warehouse list — six sites, not five
  2. 11:57, 15 Jan 2025 (diff | hist) Loss on drying 3,338 +124 add the system-suitability criteria the method actually specifies
  3. 11:32, 13 Jan 2025 (diff | hist) Peptide content 4,810 +716 clarify that mass spectrometry confirms identity, not purity
  4. 11:02, 13 Jan 2025 (diff | hist) Incretin effect 5,397 +218 ce per PP:MOS
  5. 09:25, 12 Jan 2025 (diff | hist) Reference standard 3,767 ±0 m convert a hard-coded date to the house format
  6. 10:27, 11 Jan 2025 (diff | hist) Purity claim inflation 3,067 ±0 expand §What a purity figure does establish
  7. 01:24, 11 Jan 2025 (diff | hist) List of GLP-1 receptor agonists 3,023 +157 m add see-also entries for the four articles that link here
  8. 00:09, 7 Jan 2025 (diff | hist) Sterile water for injection 3,229 +143 m state that reconstituted material should not be frozen, with the source
  9. 08:00, 6 Jan 2025 (diff | hist) WuXi TIDES 8,547 +950 move a stray full stop inside the reference
  10. 01:03, 3 Jan 2025 (diff | hist) Cold-chain freight 2,511 +126 expand §Monitoring
  11. 17:11, 28 Dec 2024 (diff | hist) Cost per milligram 1,020 ±0 fix hyphenation per PP:MOS
  12. 07:48, 28 Dec 2024 (diff | hist) Sarcopenia 2,290 +460 rm the claim that the marker predicts outcome; the cited study is cross-sectional
  13. 09:04, 26 Dec 2024 (diff | hist) Reverse-phase HPLC 3,884 ±0 add the reference standard and its traceability
  14. 08:39, 25 Dec 2024 (diff | hist) Grey market 1,800 ±0 add the reconstitution-stability sentence with its storage condition
  15. 15:03, 24 Dec 2024 (diff | hist) Cold chain 16,678 +1,155 the article confused primary and secondary drying; corrected
  16. 00:27, 20 Dec 2024 (diff | hist) Blind sampling 3,929 ±0 clarify that a certificate is a claim by its issuer
  17. 05:52, 19 Dec 2024 (diff | hist) Analytical method validation 4,003 +992 add the detection wavelength
  18. 00:18, 18 Dec 2024 (diff | hist) Cost per milligram 1,020 ±0 state that the pricing data is self-reported where it is
  19. 06:19, 8 Dec 2024 (diff | hist) Insulin secretion 4,446 +37 add the postprandial time course with its units
  20. 17:08, 4 Dec 2024 (diff | hist) Receptor bias 2,387 ±0 convert the receptor-distribution list to a table
  21. 13:05, 29 Nov 2024 (diff | hist) Peptide stability table 1,273 ±0 add the note that vial overfill is not assumed
  22. 03:38, 27 Nov 2024 (diff | hist) Semaglutide 6,658 ±0 add a hatnote pointing at the analogue with the similar name
  23. 04:08, 19 Nov 2024 (diff | hist) Underfilling 1,108 ±0 m add the note that a purity figure without water and counterion is not a mass
  24. 20:58, 16 Nov 2024 (diff | hist) Bachem Holding (Suzhou) 4,637 +1,302 add the see-also to the certificate-of-analysis article
  25. 02:03, 16 Nov 2024 (diff | hist) Lot traceability 2,794 ±0 fix the anchor on an internal link
  26. 10:52, 11 Nov 2024 (diff | hist) Mass spectrometry 3,881 +41 state the column chemistry and the gradient the figure was obtained on
  27. 14:16, 8 Nov 2024 (diff | hist) Medutest 2,738 ±0 state what the certificate actually carries, field by field
  28. 09:28, 4 Nov 2024 (diff | hist) Peptide content 3,523 +32 fix a broken wikilink
  29. 23:42, 29 Oct 2024 (diff | hist) Third-party testing 4,445 +34 alphabetise the see-also list
  30. 19:00, 29 Oct 2024 (diff | hist) Reference standard 2,872 ±0 add the counterion determination method by name
  31. 07:00, 26 Oct 2024 (diff | hist) Bacterial endotoxin test 2,929 ±0 rm the vendor name from a methodological sentence
  32. 06:54, 23 Oct 2024 (diff | hist) HOMA-IR 1,827 ±0 expand §Behaviour under weight loss and incretin therapy
  33. 00:12, 20 Oct 2024 (diff | hist) Insulin secretion 3,940 +134 state that the receptor is a class B G-protein-coupled receptor
  34. 11:43, 18 Oct 2024 (diff | hist) Subcutaneous injection 2,986 +28 state the syringe graduation the unit figure assumes
  35. 10:13, 17 Oct 2024 (diff | hist) Missed dose 2,029 +597 add the preservative point: unpreserved diluent changes the interval
  36. 00:37, 16 Oct 2024 (diff | hist) List of GLP-1 receptor agonists 2,257 ±0 add the cross-link to the parent article
  37. 07:55, 13 Oct 2024 (diff | hist) Karl Fischer titration 4,811 +330 m expand §Chemical basis
  38. 12:24, 7 Oct 2024 (diff | hist) Blind sampling 3,109 +142 expand §How this wiki handles it
  39. 21:03, 5 Oct 2024 (diff | hist) Good manufacturing practice 2,439 +666 m add the customs-detention point with its source
  40. 09:00, 29 Sep 2024 (diff | hist) Number needed to treat 1,122 +1,122 N new article: trial programme, expansion welcome
  41. 07:35, 28 Sep 2024 (diff | hist) Reference standard 2,872 ±0 add the forced-degradation conditions the claim rests on
  42. 09:00, 24 Sep 2024 (diff | hist) Exenatide 1,276 +1,276 N start article on the compound
  43. 07:54, 6 Sep 2024 (diff | hist) WuXi TIDES 4,222 +1,176 expand the product-scope row in the infobox
  44. 17:12, 5 Sep 2024 (diff | hist) Electrospray ionisation 1,326 ±0 m add the note on co-elution and what it hides
  45. 22:22, 1 Sep 2024 (diff | hist) Beta cell function 2,291 +604 m add the species in which the knockout work was done
  46. 06:49, 31 Aug 2024 (diff | hist) Beta cell function 1,687 ±0 m serial comma per PP:MOS
  47. 23:08, 30 Aug 2024 (diff | hist) High-performance liquid chromatography 3,179 ±0 state the titration endpoint and the reagent factor
  48. 04:33, 30 Aug 2024 (diff | hist) Timeline of incretin therapeutics 2,186 +341 correct the dose ladder — the maintenance dose is not the maximum dose
  49. 22:33, 29 Aug 2024 (diff | hist) Semaglutide 4,857 +54 m move the trade-name history out of the lead and into §Regulatory history
  50. 17:37, 26 Aug 2024 (diff | hist) Mass spectrometry 2,880 ±0 expand §What a mass confirms
  51. 19:58, 22 Aug 2024 (diff | hist) Tirzepatide 3,725 +54 add see also to the amylin analogue
  52. 00:44, 22 Aug 2024 (diff | hist) Medutest 2,537 +446 add the point that reports reaching this wiki are not a sample of anything
  53. 05:58, 20 Aug 2024 (diff | hist) Sterile water for injection 1,225 ±0 the example withdrew more than the syringe holds; corrected
  54. 13:04, 17 Aug 2024 (diff | hist) Batch number 1,993 ±0 clarify that a certificate is a claim by its issuer
  55. 03:22, 17 Aug 2024 (diff | hist) SURMOUNT trial programme 2,057 ±0 space between number and unit per PP:MOS
  56. 08:52, 16 Aug 2024 (diff | hist) Talk:WuXi TIDES 1,244 +96 /* Notability, and the name problem */ reply
  57. 20:18, 6 Aug 2024 (diff | hist) STEP trial programme 2,859 +516 state that the trial has reported but is not yet peer-reviewed
  58. 23:39, 24 Jul 2024 (diff | hist) Peptide synthesis 2,347 +311 m add the shelf temperature and the primary drying step to the cycle description
  59. 11:32, 23 Jul 2024 (diff | hist) High-performance liquid chromatography 2,620 ±0 add the peptide-content point: area percent alone cannot give a mass
  60. 09:01, 17 Jul 2024 (diff | hist) Retatrutide 2,444 +54 m expand §Safety signals reported to date
  61. 03:35, 12 Jul 2024 (diff | hist) Glucose-dependent insulinotropic polypeptide 2,551 ±0 correct the second-messenger pathway named in the lead
  62. 15:18, 10 Jul 2024 (diff | hist) Glucagon-like peptide-1 3,005 ±0 serial comma per PP:MOS
  63. 09:00, 8 Jul 2024 (diff | hist) Proglucagon 1,496 +1,496 N new article: incretin physiology, expansion welcome
  64. 21:35, 2 Jul 2024 (diff | hist) Adverse effects of GLP-1 receptor agonists 1,312 ±0 m expand §Body composition and other effects
  65. 04:34, 26 Jun 2024 (diff | hist) Dipeptidyl peptidase-4 2,323 ±0 expand §Evading the enzyme
  66. 03:11, 15 Jun 2024 (diff | hist) Peptide 1,981 ±0 m correct the humidity figure — relative humidity needs its temperature